Neuronetics (STIM) to Release Quarterly Earnings on Monday

Neuronetics (NASDAQ:STIM) is set to issue its quarterly earnings data before the market opens on Monday, August 12th. Analysts expect the company to announce earnings of ($0.27) per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

Neuronetics Stock Down 4.8 %

Shares of STIM opened at $1.78 on Friday. The firm has a market capitalization of $53.40 million, a P/E ratio of -1.85 and a beta of 2.32. Neuronetics has a 12-month low of $1.03 and a 12-month high of $5.07. The company has a current ratio of 5.65, a quick ratio of 5.18 and a debt-to-equity ratio of 2.15. The firm has a fifty day moving average price of $1.87 and a 200-day moving average price of $2.92.

Analyst Upgrades and Downgrades

Separately, William Blair raised shares of Neuronetics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, May 14th.

Insider Buying and Selling

In other Neuronetics news, Director Robert Cascella acquired 50,000 shares of the stock in a transaction that occurred on Thursday, June 6th. The stock was bought at an average cost of $2.05 per share, with a total value of $102,500.00. Following the completion of the purchase, the director now directly owns 244,098 shares in the company, valued at $500,400.90. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other Neuronetics news, Director Robert Cascella acquired 50,000 shares of the stock in a transaction that occurred on Thursday, June 6th. The stock was bought at an average cost of $2.05 per share, with a total value of $102,500.00. Following the completion of the purchase, the director now directly owns 244,098 shares in the company, valued at $500,400.90. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Keith J. Sullivan sold 24,162 shares of the company’s stock in a transaction dated Thursday, July 18th. The stock was sold at an average price of $1.90, for a total transaction of $45,907.80. Following the completion of the sale, the chief executive officer now directly owns 1,324,354 shares of the company’s stock, valued at $2,516,272.60. The disclosure for this sale can be found here. 9.80% of the stock is owned by insiders.

About Neuronetics

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.